765 related articles for article (PubMed ID: 10546697)
1. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial.
Heymsfield SB; Greenberg AS; Fujioka K; Dixon RM; Kushner R; Hunt T; Lubina JA; Patane J; Self B; Hunt P; McCamish M
JAMA; 1999 Oct; 282(16):1568-75. PubMed ID: 10546697
[TBL] [Abstract][Full Text] [Related]
2. Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial.
Zelissen PM; Stenlof K; Lean ME; Fogteloo J; Keulen ET; Wilding J; Finer N; Rössner S; Lawrence E; Fletcher C; McCamish M;
Diabetes Obes Metab; 2005 Nov; 7(6):755-61. PubMed ID: 16219020
[TBL] [Abstract][Full Text] [Related]
3. Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study.
Ettinger MP; Littlejohn TW; Schwartz SL; Weiss SR; McIlwain HH; Heymsfield SB; Bray GA; Roberts WG; Heyman ER; Stambler N; Heshka S; Vicary C; Guler HP
JAMA; 2003 Apr; 289(14):1826-32. PubMed ID: 12684362
[TBL] [Abstract][Full Text] [Related]
4. Effects of recombinant human leptin treatment as an adjunct of moderate energy restriction on body weight, resting energy expenditure and energy intake in obese humans.
Fogteloo AJ; Pijl H; Frölich M; McCamish M; Meinders AE
Diabetes Nutr Metab; 2003 Apr; 16(2):109-14. PubMed ID: 12846450
[TBL] [Abstract][Full Text] [Related]
5. Metabolic effects of biosynthetic growth hormone treatment in severely energy-restricted obese women.
Tagliaferri M; Scacchi M; Pincelli AI; Berselli ME; Silvestri P; Montesano A; Ortolani S; Dubini A; Cavagnini F
Int J Obes Relat Metab Disord; 1998 Sep; 22(9):836-41. PubMed ID: 9756240
[TBL] [Abstract][Full Text] [Related]
6. Pegylated human recombinant leptin (PEG-OB) causes additional weight loss in severely energy-restricted, overweight men.
Hukshorn CJ; Westerterp-Plantenga MS; Saris WH
Am J Clin Nutr; 2003 Apr; 77(4):771-6. PubMed ID: 12663271
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of subcutaneous recombinant methionyl human leptin administration in healthy subjects in the fed and fasting states: regulation by gender and adiposity.
Chan JL; Wong SL; Mantzoros CS
Clin Pharmacokinet; 2008; 47(11):753-64. PubMed ID: 18840030
[TBL] [Abstract][Full Text] [Related]
8. Leptin administration to overweight and obese subjects for 6 months increases free leptin concentrations but does not alter circulating hormones of the thyroid and IGF axes during weight loss induced by a mild hypocaloric diet.
Shetty GK; Matarese G; Magkos F; Moon HS; Liu X; Brennan AM; Mylvaganam G; Sykoutri D; Depaoli AM; Mantzoros CS
Eur J Endocrinol; 2011 Aug; 165(2):249-54. PubMed ID: 21602313
[TBL] [Abstract][Full Text] [Related]
9. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy.
Ravussin E; Smith SR; Mitchell JA; Shringarpure R; Shan K; Maier H; Koda JE; Weyer C
Obesity (Silver Spring); 2009 Sep; 17(9):1736-43. PubMed ID: 19521351
[TBL] [Abstract][Full Text] [Related]
10. Zonisamide for weight loss in obese adults: a randomized controlled trial.
Gadde KM; Franciscy DM; Wagner HR; Krishnan KR
JAMA; 2003 Apr; 289(14):1820-5. PubMed ID: 12684361
[TBL] [Abstract][Full Text] [Related]
11. Low-dose growth hormone treatment with diet restriction accelerates body fat loss, exerts anabolic effect and improves growth hormone secretory dysfunction in obese adults.
Kim KR; Nam SY; Song YD; Lim SK; Lee HC; Huh KB
Horm Res; 1999; 51(2):78-84. PubMed ID: 10352397
[TBL] [Abstract][Full Text] [Related]
12. The effects of recombinant human growth hormone (rhGH) supplementation on adipokines and C-reactive protein in obese subjects.
Albert SG; Haas MJ; Mooradian AD
Growth Horm IGF Res; 2007 Feb; 17(1):19-25. PubMed ID: 17118687
[TBL] [Abstract][Full Text] [Related]
13. Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men.
Hukshorn CJ; Saris WH; Westerterp-Plantenga MS; Farid AR; Smith FJ; Campfield LA
J Clin Endocrinol Metab; 2000 Nov; 85(11):4003-9. PubMed ID: 11095423
[TBL] [Abstract][Full Text] [Related]
14. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.
Davidson MH; Hauptman J; DiGirolamo M; Foreyt JP; Halsted CH; Heber D; Heimburger DC; Lucas CP; Robbins DC; Chung J; Heymsfield SB
JAMA; 1999 Jan; 281(3):235-42. PubMed ID: 9918478
[TBL] [Abstract][Full Text] [Related]
15. Effect of a 24-week weight management program on serum leptin level in correlation to anthropometric measures in obese female: A randomized controlled clinical trial.
Rashad NM; Sayed SE; Sherif MH; Sitohy MZ
Diabetes Metab Syndr; 2019; 13(3):2230-2235. PubMed ID: 31235162
[TBL] [Abstract][Full Text] [Related]
16. A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion.
Lustig RH; Greenway F; Velasquez-Mieyer P; Heimburger D; Schumacher D; Smith D; Smith W; Soler N; Warsi G; Berg W; Maloney J; Benedetto J; Zhu W; Hohneker J
Int J Obes (Lond); 2006 Feb; 30(2):331-41. PubMed ID: 16158082
[TBL] [Abstract][Full Text] [Related]
17. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy.
Lee JH; Chan JL; Sourlas E; Raptopoulos V; Mantzoros CS
J Clin Endocrinol Metab; 2006 Jul; 91(7):2605-11. PubMed ID: 16636130
[TBL] [Abstract][Full Text] [Related]
18. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients.
Kopelman P; Bryson A; Hickling R; Rissanen A; Rossner S; Toubro S; Valensi P
Int J Obes (Lond); 2007 Mar; 31(3):494-9. PubMed ID: 16953261
[TBL] [Abstract][Full Text] [Related]
19. Effect of Weight Loss via Severe vs Moderate Energy Restriction on Lean Mass and Body Composition Among Postmenopausal Women With Obesity: The TEMPO Diet Randomized Clinical Trial.
Seimon RV; Wild-Taylor AL; Keating SE; McClintock S; Harper C; Gibson AA; Johnson NA; Fernando HA; Markovic TP; Center JR; Franklin J; Liu PY; Grieve SM; Lagopoulos J; Caterson ID; Byrne NM; Sainsbury A
JAMA Netw Open; 2019 Oct; 2(10):e1913733. PubMed ID: 31664441
[TBL] [Abstract][Full Text] [Related]
20. Weight reduction effects of a black soy peptide supplement in overweight and obese subjects: double blind, randomized, controlled study.
Kwak JH; Ahn CW; Park SH; Jung SU; Min BJ; Kim OY; Lee JH
Food Funct; 2012 Oct; 3(10):1019-24. PubMed ID: 22739624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
